Karen Weintraub is a freelance writer based in Boston, Massachusetts.
Karen Weintraub
Freelance Writer
Simons Foundation/Freelance
From this contributor
Technique follows calcium trail to track changes in signaling
Researchers have genetically engineered neurons to fluoresce in response to the calcium signals emitted when they fire, according to a study published 18 October in Neuron.
Technique follows calcium trail to track changes in signaling
By
Karen Weintraub
24 October 2012 | 2 min read
Researchers uncover new drug target for fragile X
Deleting an enzyme that regulates protein synthesis reverses some of the molecular and behavioral deficits in a mouse model of fragile X syndrome, according to research published 2 October in Neuron.
Researchers uncover new drug target for fragile X
By
Karen Weintraub
4 October 2012 | 5 min read
Drug improves social deficits in fragile X syndrome
A drug called arbaclofen improves behavioral problems in people with fragile X syndrome, an inherited condition that can lead to mental retardation and autism, according to the results of a clinical trial published today in Science Translational Medicine. A second study published in the same journal showed that the drug restores normal brain function in a mouse model of the disorder.
Drug improves social deficits in fragile X syndrome
By
Karen Weintraub
19 September 2012 | 5 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read